TETRAPHASE PHARMACEUTICALS I's ticker is TTPHXXXX and the CUSIP is 88165N105. A total of 89 filers reported holding TETRAPHASE PHARMACEUTICALS I in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $1,000 | -85.7% | 1,216 | -78.1% | 0.00% | – |
| Q1 2019 | $7,000 | +40.0% | 5,541 | +16.3% | 0.00% | – |
| Q4 2018 | $5,000 | -58.3% | 4,766 | +5.8% | 0.00% | – |
| Q3 2018 | $12,000 | 0.0% | 4,506 | +35.8% | 0.00% | – |
| Q2 2018 | $12,000 | -89.1% | 3,319 | -90.8% | 0.00% | – |
| Q1 2018 | $110,000 | -88.3% | 35,991 | -75.9% | 0.00% | -100.0% |
| Q4 2017 | $939,000 | -12.7% | 149,055 | -5.2% | 0.00% | 0.0% |
| Q3 2017 | $1,075,000 | -27.0% | 157,192 | -23.9% | 0.00% | -25.0% |
| Q2 2017 | $1,473,000 | -3.0% | 206,574 | +25.1% | 0.00% | 0.0% |
| Q1 2017 | $1,518,000 | +188.0% | 165,190 | +26.3% | 0.00% | +100.0% |
| Q4 2016 | $527,000 | +6.2% | 130,809 | +1.0% | 0.00% | +100.0% |
| Q3 2016 | $496,000 | +23.7% | 129,483 | +38.8% | 0.00% | 0.0% |
| Q2 2016 | $401,000 | – | 93,303 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 1,048,642 | $3,219,000 | 0.50% |
| Virtus ETF Advisers LLC | 130,920 | $402,000 | 0.35% |
| 683 Capital Management, LLC | 600,000 | $1,842,000 | 0.16% |
| Tekla Capital Management LLC | 859,322 | $2,638,000 | 0.10% |
| DOW CHEMICAL CO /DE/ | 65,000 | $200,000 | 0.07% |
| Alambic Investment Management, L.P. | 115,834 | $356,000 | 0.05% |
| A.R.T. Advisors, LLC | 262,896 | $807,000 | 0.03% |
| Candriam S.C.A. | 520,613 | $1,598,000 | 0.03% |
| Man Group plc | 1,674,341 | $5,140,000 | 0.02% |
| Baker Brothers Advisors | 935,000 | $2,870,000 | 0.02% |